iTeos Therapeutics (ITOS) Expected to Announce Quarterly Earnings on Friday

Posted by Defense World Staff on May 2nd, 2025

iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Friday, May 9th. Analysts expect iTeos Therapeutics to post earnings of ($0.94) per share and revenue of $1.80 million for the quarter.

iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) last posted its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.14. On average, analysts expect iTeos Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

iTeos Therapeutics Price Performance

iTeos Therapeutics stock opened at $7.50 on Friday. The stock’s fifty day moving average is $6.57 and its two-hundred day moving average is $7.55. The stock has a market cap of $286.46 million, a PE ratio of -2.38 and a beta of 1.43. iTeos Therapeutics has a 1-year low of $4.80 and a 1-year high of $18.75.

Wall Street Analyst Weigh In

ITOS has been the topic of several research reports. Wells Fargo & Company dropped their price objective on iTeos Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a report on Tuesday. Wedbush reissued an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a report on Wednesday, March 5th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price objective on shares of iTeos Therapeutics in a research report on Thursday, March 6th. Finally, JPMorgan Chase & Co. cut their price target on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th.

Get Our Latest Analysis on iTeos Therapeutics

iTeos Therapeutics Company Profile

(Get Free Report)

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.